{"links":{"html":"https://www.erudio.com/reports/act-1-nct00646854","json":"https://www.erudio.com/reports/act-1-nct00646854.json","markdown":"https://www.erudio.com/reports/act-1-nct00646854.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"act-1-00646854"}},"request":"https://www.erudio.com/contact?report=act-1-00646854"},"offer":{"cited_commentary_sources":2,"verified_hcp_statements":5,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":2,"optional":true,"price_per_verified_person_usd":15,"price_usd":30,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"act-1-nct00646854"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=act-1-00646854","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/act-1-nct00646854","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T03:07:54.121701Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":4,"no_commentary_found":4},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Event-free Survival"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"conditionsModule","source_count":0,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":1,"coverage":"discussed","id":"A1","source_count":1,"title":"CD52 assessment: immunohistochemistry versus flow analysis"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":1,"title":"Broader X+CHOP interest and relayed response rates"}],"counts":{"cited_sources":2,"claims_by_expression_type":{"comparison":2,"interpretation":1,"opinion":1,"restatement":1},"claims_by_kind":{"source_observation":5},"clinician_statements":2,"evidence_units":4,"findings":3,"organisational_accounts":1,"people_cited":2,"people_identity_verified":2,"people_total":2,"screened_sources":33,"verified_claims":5},"findings_index":[{"id":"F1","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":1,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"The no-survival-benefit interpretation spans several studies"},{"id":"F2","structure":{"claims":1,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":0},"has_counterview":false,"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"CD52 assessment draws a methodological criticism"},{"id":"F3","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Broader X+CHOP interest includes a relayed high-response-rate assessment"}],"medical_affairs_question":"How should response-rate interest be framed alongside a nonspecific survival conclusion and CD52-assessment concerns?","sections":{"analysis":[{"id":"section-1","level":3,"title":"Keep the cross-study survival conclusion separate from an ACT-1 endpoint result"},{"id":"section-2","level":3,"title":"CD52 assessment is a methods concern, not a biomarker result"},{"id":"section-3","level":3,"title":"Response-rate interest is broader, and the favorable assessment is relayed"},{"id":"section-4","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Event-free Survival"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T03:07:54.121701Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T03:15:53Z","record_hash":"0b4dec5abdec66a9bcf9f3caa5e03adfc774a888d46069116af94df70116842a","release_hash":"bfb46da31bc8ef0e68297741f34d78631f8150cb8a9557ad711b8bcfd525fde1","report_id":"erudio-nct00646854","run_id":"a47cc15b-34cf-42d1-bd25-73a0e8f60c9f","schema_version":"5.0","slug":"act-1-00646854","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ACT-1 asks whether adding alemtuzumab to two-weekly CHOP improves event-free survival in younger patients with untreated systemic peripheral T-cell lymphoma receiving autologous transplant consolidation. Commentary comes from X posts. The discussion turns on whether alemtuzumab adds survival benefit to CHOP, with one speaker offering a negative interpretation across studies. Further questions concern CD52 assessment methods and how to interpret interest in response rates with broader CHOP combinations.","meta_description":"33 sources screened · 5 verified statements (2 from clinicians verified by NPI or staff page) from 2 sources · 3 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-6079344453d8215d0834","claim-79ace4c41d3bc12b028e"],"id":"F1","paraphrase":"An X post prompts a methodological question: how should a survival interpretation spanning alemtuzumab–CHOP studies be distinguished from conclusions about ACT-1-specific endpoints?","publication_caveats":["Short quotations should be accompanied by a link to the original post."],"source_channel":"x_thread","source_date":"2019-03-02","title":"The no-survival-benefit interpretation spans several studies"}]},"publication":{"approved_at":"2026-10-31T03:15:53Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":33},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The findings rest on two short X posts. Relevant discussion that does not name the trial may be missing, and two passages were not fully assessed for clinician views.","No results publication for NCT00646854 or trial protocol was available among the sources reviewed for this edition; the posts cannot substitute for a trial-specific quantitative assessment.","The survival statement lacks an identified endpoint, time point and estimate; the relayed response-rate statement lacks an identified study, numerical rate, definition and time point.","These statements do not establish treatment recommendations, safety reassurance, stem-cell-harvest feasibility or agreement across HCPs."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":2,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":2},"count":2,"evidence_window":{"end":"2023-06-14","start":"2019-03-02"},"retrieval_snapshot":"2026-10-31T02:38:17.144094Z","timeline":[{"count":1,"week":"2019-W09"},{"count":1,"week":"2023-W24"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT00646854:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00646854:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-26cnc5l42jvqualc2vjlhml2-3lkgmt5wvvb2p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3gm3wqojlafxmt4scfiw47xm-3ma4wesekqs2f","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-5e3pfsjw4gj3yi4jd2afymua-3mvd6btet7f2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-62do2exixnrqzvrhodk5c5nv-3lazdfjc47c2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cnjmnee3dfsrfeqmwrmxaeai-3m4h7vxoros2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-dmnxczsx5w7adk4l457rikrm-3m7bmknbxur2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-eijqdygh72wuei7faamrclpc-3lne3zfnakc2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-gbd4dskldh6jyfquke6vm2ag-3lzqhiqs56k2r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-gbd4dskldh6jyfquke6vm2ag-3lzwbeyydbs2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-gzvucotqb7rp6y2lxw4cxl7p-3kiftfmr4r62g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-iidfr4ee72rynh4277xftz4d-3ma3p3w2tig2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-iidfr4ee72rynh4277xftz4d-3md7tegxkew2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-k664lsvmnra3cqy24ffepr2o-3lodmmei3c22o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-oxh2lmowuusxjqn4f4usyjk5-3ljkmihfsds26","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7590b2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:99cd51","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:af5cf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1101745469452095489:a3b2baf3-4de4-49b7-9c0b-7403794d73ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1117076553274408960:648ce7dc-311e-420a-aaec-92314d8fb20b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1459928401507192841:98eff636-c758-4a69-a9cf-e90c61426b5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470469872870121482:d49d83bd-c514-410c-92cc-688f9d2c47de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1473709562742124553:b8889271-f1fd-4626-93bc-a8aacdd4bfd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1489768282680926209:33547743-a289-4534-9238-1c83e7d96767","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1626016384562917378:7ca3a1b9-7f20-4665-a47c-ebcc947656ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1668886356574056449:6f7c0db1-c24e-41d2-877f-2e717b29243e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1675528718050000896:6b2d5e4e-2f91-4116-bdf5-60f58e81d8c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717538838523081184:4601c7eb-3a1b-4249-90a8-dcffac5da11a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1795616483722342866:ada1dce8-4e8e-46ee-bc80-210c9007c155","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1808753415159226540:0898d5c8-0b26-4e1a-892d-41d6b4891aa3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1859680875467948102:08f799b0-6d65-4779-95e0-1f390aa0d9a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113636755773513964:a40584ec-6e3a-4ddd-bf54-6e2c4f5da582","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QwF_9Dqh0t4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:wv2D1LmvzMg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":14,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":33},"count":33,"evidence_window":{"end":"2026-10-25","start":"2019-03-02"},"retrieval_snapshot":"2026-10-31T02:50:36.151834Z","timeline":[{"count":1,"week":"2019-W09"},{"count":1,"week":"2019-W15"},{"count":1,"week":"2021-W45"},{"count":1,"week":"2021-W46"},{"count":1,"week":"2021-W50"},{"count":1,"week":"2021-W51"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2023-W07"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2024-W01"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W46"},{"count":2,"week":"2024-W47"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W22"},{"count":2,"week":"2025-W39"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W49"},{"count":2,"week":"2025-W51"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: chop14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus g-csf, combined with alemtuzumab","status":"unmapped"},{"reason":"Unmapped registry intervention: chop14 chemotherapy (see specification under arm b) plus g-csf","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Lymphoma, T-Cell, Peripheral","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"ACT-1","aliases":["ACT-1","Alemtuzumab and CHOP in T-cell Lymphoma","A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas"],"brief_title":"Alemtuzumab and CHOP in T-cell Lymphoma","collaborators":["GCP-unit at Aarhus University Hospital, Aarhus, Denmark"],"conditions":["Lymphoma, T-Cell, Peripheral"],"display_condition":"previously untreated peripheral T-cell lymphoma","display_interventions":[["alemtuzumab"]],"enrollment":{"count":136,"type":"ACTUAL"},"interventions":[{"name":"CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"CHOP14 chemotherapy (see specification under Arm B) plus G-CSF","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT00646854","official_title":"A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2016-12-31","type":"ACTUAL"},"primary_endpoints":[{"measure":"Event-free Survival","timeFrame":"The EFS is defined by the time between day of randomization until an event occurs, up to 96 months"}],"registered_date":{"date":"2008-03-31","type":"ESTIMATED"},"registry_last_updated":"2019-03-01","registry_url":"https://clinicaltrials.gov/study/NCT00646854","short_name":"ACT-1","short_name_basis":"registry_acronym","sponsor":"Aarhus University Hospital","start_date":{"date":"2008-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"2006-006130-17","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}